CSL222 (AAV5-hFIXco-Padua) for hemophilia b

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Aug 2023: Trial registered, NCT06003387
  2. 30 Jan 2024: Trial started, NCT06003387

The trials

NCT06003387: Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

State
Under way
Phase
Phase 3
People
35 planned
Started
30 Jan 2024
Primary completion
4 Oct 2028
Arms
CSL222
Results
None posted
  1. 22 Aug 2023: Trial registered
  2. 30 Jan 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Gene therapy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.